Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 173-178

  Gattorno, Marco ^a   Obici, Laura ^b   Cattalini, Marco ^c   Tormey, Vincent ^d   Abrams, Ken ^e   Davis, Nicole ^e   Speziale, Antonio ^e   Bhansali, Suraj G ^e   Martini, Alberto ^a,f   Lachmann, Helen J ^g  

^a G GASLINI INSTITUTE   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY HOSPITAL GALWAY   (Ireland)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF GENOA   (Italy)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT; SERUM AMYLOID A; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTITIS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FEVER; FOOT MALFORMATION; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; INTESTINE OBSTRUCTION; KNEE MENISCUS RUPTURE; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MALE; MUSCULOSKELETAL PAIN; MYALGIA; OROPHARYNX PAIN; OTALGIA; PARESTHESIA; PERICARDITIS; PHARMACOKINETIC PARAMETERS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RASH; RECURRENT DISEASE; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THORAX PAIN; TOOTH PAIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; FAMILIAL MEDITERRANEAN FEVER; GENETICS; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973333178     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-209031     Document Type: Article

References (24)

1. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
2. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS). Emerging concepts of an autoinflammatory disorder. Medicine 2002; 81: 349-68.
3. Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014; 73: 2160-7.
4. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012; 71: 1177-82.
5. Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose escalation study. Arthritis Rheum 2012; 64: 908-13.
6. Quillinan N, Mannion G, Mohammad A, et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 2011; 70: 1692-3.
7. Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
8. Jacobelli S, André M, Alexandara JF, et al. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 2007; 46: 1212-13.
9. Drewe E, Powell RJ, McDermott EM. Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 2007; 46: 1865-6.
10. Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the anti-inflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009; 60: 619-25.
11. Gattorno M, Martini A. Beyond the NLRP3 inflammasome. Autoinflammatory disorders reach adolescence. Arthritis Rheum 2013; 65: 1137-47.
12. Bachetti T, Chiesa S, Castagnola P, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 2013; 72: 1044-52.
13. Simon A, Bodar EJ, van der Hilst JCH, et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med 2004; 117: 208-10.
14. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
15. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36.
16. Dhimolea E. Canakinumab. mAbs 2010; 2: 3-13.
17. Brizi MG, Galeazzi M, Lucherini OM, et al. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 2012; 156: 907-8.
18. Lopalco G, Rigante D, Vitale A, et al. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol 2015; 34: 807-9.
19. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
20. Obici L, Meini A, Cattalini M, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011; 70: 1511-12.
21. Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42: 235-9.
22. Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers. https://clinicaltrials.gov/ct2/show/NCT02059291.ClinicalTrials.gov Identifier: NCT02059291 (accessed 15 Apr 2016).
23. Church LD, McDermott MF. Canakinumab: a human anti-IL-1b monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev Clin Immunol 2010; 6: 831-41.
24. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.